GH Research Plc
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About GH Research Plc
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
/ 
Frequently asked questions
To buy GH Research Plc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for GH Research Plc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for GH Research Plc is GHRS:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
GH Research Plc has its primary listing on NASDAQ. You can trade GH Research Plc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, GH Research Plc is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include GH Research Plc as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like GH Research Plc.